287 related articles for article (PubMed ID: 2581259)
1. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Medof ME; Kinoshita T; Silber R; Nussenzweig V
Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
3. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
4. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
[TBL] [Abstract][Full Text] [Related]
5. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
7. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
[TBL] [Abstract][Full Text] [Related]
9. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
[TBL] [Abstract][Full Text] [Related]
10. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
Kinoshita T; Rosenfeld SI; Nussenzweig V
J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
[TBL] [Abstract][Full Text] [Related]
11. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
[TBL] [Abstract][Full Text] [Related]
12. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
[TBL] [Abstract][Full Text] [Related]
13. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase.
Sugarman J; Devine DV; Rosse WF
Blood; 1986 Sep; 68(3):680-4. PubMed ID: 2427138
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
Schultz DR
Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
[TBL] [Abstract][Full Text] [Related]
17. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes.
Hatanaka M; Inai S; Matsumoto M; Miyagawa S; Masaoka T; Kanamaru A; Kawakita M; Yonemura Y; Sugita Y; Seya T
Clin Immunol Immunopathol; 1993 Oct; 69(1):52-9. PubMed ID: 7691453
[TBL] [Abstract][Full Text] [Related]
18. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
